CN110114365B - 羟基苯甲酸衍生物、方法及其用途 - Google Patents

羟基苯甲酸衍生物、方法及其用途 Download PDF

Info

Publication number
CN110114365B
CN110114365B CN201780081193.XA CN201780081193A CN110114365B CN 110114365 B CN110114365 B CN 110114365B CN 201780081193 A CN201780081193 A CN 201780081193A CN 110114365 B CN110114365 B CN 110114365B
Authority
CN
China
Prior art keywords
antioxben
mitochondrial
disease
compound
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780081193.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110114365A (zh
Inventor
玛丽亚·费尔南达·马丁斯·博格斯
保罗·若热·戈维亚·西蒙斯·达·西尔瓦·奥利韦拉
若泽·卡洛斯·桑托斯·特谢拉
费尔南多·卡希德·费金
安娜·卡塔里娜·戈梅斯·奥利韦拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade do Porto
Centro de Neurociencias e Biologia Celular
Original Assignee
Universidade do Porto
Centro de Neurociencias e Biologia Celular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade do Porto, Centro de Neurociencias e Biologia Celular filed Critical Universidade do Porto
Publication of CN110114365A publication Critical patent/CN110114365A/zh
Application granted granted Critical
Publication of CN110114365B publication Critical patent/CN110114365B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201780081193.XA 2016-12-29 2017-12-29 羟基苯甲酸衍生物、方法及其用途 Active CN110114365B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT10981816 2016-12-29
PT109818 2017-12-29
PCT/IB2017/058508 WO2018122789A1 (en) 2016-12-29 2017-12-29 Hydroxybenzoic acid derivatives, methods and uses thereof

Publications (2)

Publication Number Publication Date
CN110114365A CN110114365A (zh) 2019-08-09
CN110114365B true CN110114365B (zh) 2022-12-13

Family

ID=61074472

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780081193.XA Active CN110114365B (zh) 2016-12-29 2017-12-29 羟基苯甲酸衍生物、方法及其用途

Country Status (8)

Country Link
US (1) US11078222B2 (https=)
EP (1) EP3562830B1 (https=)
JP (2) JP2020503280A (https=)
KR (1) KR102750630B1 (https=)
CN (1) CN110114365B (https=)
BR (1) BR112019011303B1 (https=)
CA (1) CA3048966A1 (https=)
WO (1) WO2018122789A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021085906A1 (ko) * 2019-10-30 2021-05-06 주식회사 퓨전바이오텍 미토콘드리아 표적 화합물 및 이를 포함하는 노화 관련 질환의 치료 또는 예방을 위한 조성물
WO2023053059A1 (en) * 2021-09-30 2023-04-06 Universidade Do Porto Antifouling compound, method and uses thereof
US20250312360A1 (en) * 2022-05-13 2025-10-09 Virginia Tech Intellectual Properties, Inc. Mitochondrial antioxidant treatment for cask-linked neurodevelopmental disorders
KR20240040435A (ko) * 2022-09-21 2024-03-28 울산과학기술원 미토콘드리아 표적 화합물을 유효성분으로 포함하는 망막 변성 치료용 약학적 조성물
KR102894216B1 (ko) * 2022-12-15 2025-12-18 울산과학기술원 Trap-1 억제제
CN116210697B (zh) * 2023-03-02 2024-05-14 西北农林科技大学 反式肉桂酸在提高苹果树腐烂病抗性中的应用
KR20250126454A (ko) * 2024-02-16 2025-08-25 울산과학기술원 암 세포의 티오에스테라제 및 활성산소종에 의해 자가 조립 중합되는 단량체 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459291A (zh) * 2009-04-27 2012-05-16 Mcw研究基金会股份有限公司 神经保护性化合物和它们的应用
CN105873936A (zh) * 2013-11-22 2016-08-17 医药研究委员会 线粒体靶向的二羰基螯合化合物
CN109328062A (zh) * 2016-03-08 2019-02-12 密执安大学评议会 小分子活性氧簇诱导剂和线粒体活性抑制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843896B (zh) * 2016-10-14 2022-12-20 波尔图大学 羟基肉桂酸衍生物、方法及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459291A (zh) * 2009-04-27 2012-05-16 Mcw研究基金会股份有限公司 神经保护性化合物和它们的应用
CN105873936A (zh) * 2013-11-22 2016-08-17 医药研究委员会 线粒体靶向的二羰基螯合化合物
CN109328062A (zh) * 2016-03-08 2019-02-12 密执安大学评议会 小分子活性氧簇诱导剂和线粒体活性抑制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Discovery of a new mitochondria permeability transition pore (mPTP) inhibitor based on gallic acid;Jose Teixeira et al;《JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY》;20181231;第33卷;第567-576页 *
Hydroxybenzoic Acid Derivatives as Dual-Target Ligands: Mitochondriotropic Antioxidants and Cholinesterase Inhibitors;Catarina Oliveira et al;《Front. Chem.》;20180423;第6卷;第1-17页 *

Also Published As

Publication number Publication date
EP3562830C0 (en) 2023-06-07
WO2018122789A1 (en) 2018-07-05
CA3048966A1 (en) 2018-07-05
JP2020503280A (ja) 2020-01-30
EP3562830B1 (en) 2023-06-07
BR112019011303A2 (pt) 2019-10-08
US11078222B2 (en) 2021-08-03
BR112019011303B1 (pt) 2023-03-14
JP2023051961A (ja) 2023-04-11
EP3562830A1 (en) 2019-11-06
CN110114365A (zh) 2019-08-09
KR102750630B1 (ko) 2025-01-06
KR20190132622A (ko) 2019-11-28
JP7689690B2 (ja) 2025-06-09
US20190330249A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
CN110114365B (zh) 羟基苯甲酸衍生物、方法及其用途
Teixeira et al. Development of a mitochondriotropic antioxidant based on caffeic acid: proof of concept on cellular and mitochondrial oxidative stress models
CN109843896B (zh) 羟基肉桂酸衍生物、方法及其用途
Silvia et al. Novel molecular combination deriving from natural aminoacids and polyphenols: Design, synthesis and free-radical scavenging activities
EP4226919A1 (en) Ferroptosis inhibitor
EP3129014B1 (fr) Nouveaux composes organo-selenies, procédé de fabrication et applications en pharmacie comme agents anti-tumoraux
US20090247472A1 (en) Type 1, 4-naphtoquinone compounds, compositions comprising them and use of these compounds as anti-cancer agents
RU2685502C2 (ru) Терапевтические агенты для применения в профилактике и/или лечении гиперкинетических двигательных расстройств
JP2019518029A (ja) グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法
JP7635923B2 (ja) 化合物およびその用途
EP3353186B1 (en) Highly efficient nrf2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
JP6173440B2 (ja) 新規美白剤
EP3594209A1 (en) Lipophenolic flavonoid derivatives useful to reduce carbonyl and oxidative stresses (cos)
CN116731305A (zh) 一种抗肿瘤大环内酯聚合物及其制备方法和应用
CN115087487A (zh) 使用维甲酰胺治疗皮肤病的组合物和方法
HK40081058A (en) Compound and use thereof
Neuzil et al. 4 Mitocans

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant